Qualis Health

qualishealth.org

Qualis Health is a national leader in improving care delivery and patient outcomes, working with clients throughout the public and private sector to advance the quality, efficiency, and value of healthcare for millions of Americans every day. We deliver solutions to ensure that our partners transform the care they provide, with a focus on process improvement, care management, and effective use of health information technology.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PRESSURE BIOSCIENCES ANNOUNCES THE ACHIEVEMENT OF A CRITICAL MILESTONE IN REVOLUTIONARY NANOEMULSIFICATION TECHNOLOGY DEVELOPMENT

Pressure BioSciences, Inc. | October 07, 2020

news image

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("...

Read More

MedTech, Industrial Impact

SONOMA BIOTHERAPEUTICS AND REGENERON ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE TREG CELL THERAPIES FOR AUTOIMMUNE DISEASES

Businesswire | April 03, 2023

news image

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T ce...

Read More

Cell and Gene Therapy

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

news image

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More

Cell and Gene Therapy, Industrial Impact

EDITAS MEDICINE ANNOUNCES PUBLICATION IN NATURE BIOTECHNOLOGY OF COMPREHENSIVE SLEEK GENE EDITING TECHNOLOGY DATA

Globenewswire | May 02, 2023

news image

Editas Medicine, Inc. a clinical stage genome editing company, announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK gene editing technology. Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge, SLEEK was developed to enable high knock-in efficiency ...

Read More
news image

PRESSURE BIOSCIENCES ANNOUNCES THE ACHIEVEMENT OF A CRITICAL MILESTONE IN REVOLUTIONARY NANOEMULSIFICATION TECHNOLOGY DEVELOPMENT

Pressure BioSciences, Inc. | October 07, 2020

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("...

Read More
news image

MedTech, Industrial Impact

SONOMA BIOTHERAPEUTICS AND REGENERON ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE TREG CELL THERAPIES FOR AUTOIMMUNE DISEASES

Businesswire | April 03, 2023

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T ce...

Read More
news image

Cell and Gene Therapy

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More
news image

Cell and Gene Therapy, Industrial Impact

EDITAS MEDICINE ANNOUNCES PUBLICATION IN NATURE BIOTECHNOLOGY OF COMPREHENSIVE SLEEK GENE EDITING TECHNOLOGY DATA

Globenewswire | May 02, 2023

Editas Medicine, Inc. a clinical stage genome editing company, announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK gene editing technology. Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge, SLEEK was developed to enable high knock-in efficiency ...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us